Showing results (71-80 of 93) with videos related to
Sort By:
Pageof 10
Neurology|November 23, 2000
An extended 5'-tau susceptibility haplotype in progressive supranuclear palsyJ J Higgins, L I Golbe, A De Biase, et al.Neurology|December 1, 2010
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of NeurologyE M Cheng, S Tonn, R Swain-Eng, et al.Headache|May 1, 1990
A controlled evaluation of the addition of cognitive therapy to a home-based biofeedback and relaxation treatment of vascular headacheE B Blanchard, K A Appelbaum, N L Nicholson, et al.Neurology|January 1, 1993
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's diseaseW J Weiner, S A Factor, J R Sanchez-Ramos, et al.Journal of Neural Transmission. Supplementum|January 1, 1995
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's diseaseE S Molho, S A Factor, W J Weiner, et al.Neurology|June 11, 2003
Longitudinal outcome of Parkinson's disease patients with psychosisS A Factor, P J Feustel, J H Friedman, et al.Clinical Neuropharmacology|May 10, 2000
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesiaR A Hauser, J Friedlander, T A Zesiewicz, et al.Parkinsonism & Related Disorders|December 3, 2014
Freezing of gait subtypes have different cognitive correlates in Parkinson's diseaseS A Factor, M K Scullin, A B Sollinger, et al.Neurology|April 12, 2006
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyR Pahwa, S A Factor, K E Lyons, et al.Neurology|April 4, 2007
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseR Pahwa, M A Stacy, S A Factor, et al.Pageof 10